Perfil
Dean A.
Falb worked as Vice President-Research & Development at Stryker Corp.
from 2005 to 2012.
He also worked as Senior Vice President-Research & Development at Praecis Pharmaceuticals, Inc. and as Chief Scientific Officer at LogicBio Therapeutics, Inc. In 2013, he became the Chief Technology Officer at Synlogic, Inc. Dr. Falb holds a doctorate degree from Harvard University and an undergraduate degree from Purdue University.
Antiguos cargos conocidos de Dean A. Falb.
| Empresas | Cargo | Fin |
|---|---|---|
| SYNLOGIC, INC. | Director Técnico/Científico/I+D | 01/05/2018 |
| STRYKER CORPORATION | Director Técnico/Científico/I+D | 01/01/2012 |
| LOGICBIO THERAPEUTICS, INC. | Director Técnico/Científico/I+D | - |
Praecis Pharmaceuticals, Inc.
 Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Director Técnico/Científico/I+D | - |
Formación de Dean A. Falb.
| Harvard University | Doctorate Degree |
| Purdue University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SYNLOGIC, INC. | Health Technology |
| STRYKER CORPORATION | Health Technology |
| Empresas privadas | 2 |
|---|---|
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Dean A. Falb
